AbbVie (NYSE: ABBV) and Boehringer Ingelheim’s Skyrizi performed better than Novartis‘ (NYSE: NVS) Cosentyx in a head-to-head late stage clinical trial in patients with the plaque psoriasis, an autoimmune skin disease.
After 16 weeks of treatment, Skyrizi was deemed non-inferior to Cosentyx — the clinical trial way of saying “not worse than” — with 74% of patients taking Skyrizi having at least a 90% improvement in the Psoriasis Area and Severity Index (PASI 90) compared to the start of the study, while 66% of patients taking Cosentyx achieved PASI90.
After a year of treatment, the efficacy of the drugs had separated with 87% of the patients taking Skyrizi reaching PASI 90, statistically better than the 57% of the patients taking Cosentyx who met the goal.
Skyrizi beat Cosentyx in other measurements at one year, including PASI 100 and PASI 75, which require 100% and 75% improvement in the PASI score, respectively, as well as the number of patients who were scored as clear or almost clear on the Physician Global Assessment.
<img alt="Dermatologist examining a patient's back" src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial Read More